Groupe Bruxelles Lambert (ENXTBR:GBLB) is attracting close attention from investors lately after shares posted steady gains over the past month, climbing 3% and up 7% over the past 3 months. The moves have many wondering what is driving this trend. See our latest analysis for Groupe Bruxelles Lambert. Zooming out, Groupe Bruxelles Lambert's steady share price climb this quarter comes after a generally positive 12-month period. A 1-year total shareholder return of 18.3% highlights momentum...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.